Ulcerative colitis (UC) is one of the major subtypes of inflammatory bowel disease. This chronic disease primarily causes tissue damage and subsequent inflammatory response over the whole colon. Most UC patients often suffer from the alternating states of clinical relapse and remission which leads to severe deterioration of their quality of life. To date, there is no curative treatment for UC patients.

CDD-2103 is a Chinese herbal formulation that has been clinically applied to be effective in maintaining UC remission. By drawing together expertise with traditional Chinese Medicine, pharmacognosy, pharmacology, and bioinformatics, our research programme aims to develop CDD-2103 as a new drug based on the requirement of NMPA, China, and further investigate the mechanistic understanding of CDD-2103 on UC.